Angiogenesis as targeted breast cancer therapy

Breast

Volumn 16, Issue 2 SUPPL., 2007, Pages 17-19

  Hayes, Daniel F ^a   Miller, Kathy ^b   Sledge, George ^b  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Bevacizumab; Breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; LOW DRUG DOSE; LYMPH NODE METASTASIS; METASTASIS; MONOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

EID: 35648973650     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.07.003     Document Type: Article

References (14)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
2. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5 Suppl. 1 (2000) 37-44
3. Weidner N., Semple J.P., Welch W.R., and Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324 1 (1991) 1-8
4. Shih T., and Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28 11 (2006) 1779-1802
5. Cobleigh M.A., Langmuir V.K., Sledge G.W., et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 30 5 (Suppl. 16) (2003) 117-124
6. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23 4 (2005) 792-799
7. Miller K.D., Wang M., Gralow J., et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for local recurrent or metastatic breast cancer: a trial coordinated by ECOG (E2100). Breast Cancer Res Treat 94 (2005) S6 [abstract 3]
8. Wedam S.B., Low J.A., Yang S.X., et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24 5 (2006) 769-777
9. Chow L.Q., and Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25 7 (2007) 884-896
10. Poreba M., Jazwiec B., Kuliczkowski K., and Poreba R. Circulating endothelial cells, endothelial precursors, VEGF and bFGF concentrations in patients with acute leukemias, lymphomas and myelomas. Pol Arch Med Wewn 113 1 (2005) 27-34
11. Goon P.K., Boos C.J., and Lip G.Y. Circulating endothelial cells: markers of vascular dysfunction. Clin Lab 51 9/10 (2005) 531-538
12. Goon P.K., Lip G.Y., Boos C.J., Stonelake P.S., and Blann A.D. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8 2 (2006) 79-88
13. Man S., Bocci G., Francia G., et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 62 10 (2002) 2731-2735
14. Bertolini F., Paul S., Mancuso P., et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 63 15 (2003) 4342-4346